fzr Antibody (AR38.2): sc-53291
- fzr Antibody (AR38.2) is a mouse monoclonal IgG1 κ provided at 200 µg/ml
- raised against recombinant fzr of human origin
- recommended for detection of fzr of mouse, rat and human origin by WB, IP, IF and IHC(P)
- m-IgGκ BP-HRP is the preferred secondary detection reagent for fzr Antibody (AR38.2) for WB and IHC(P) applications. This reagent is now offered in a bundle with fzr Antibody (AR38.2) (see ordering information below). For additional m-IgGκ BP conjugates see our complete list of Mouse IgG Binding Proteins.
QUICK LINKS
SEE ALSO...
fzr Antibody (AR38.2) is a mouse monoclonal IgG1 antibody that detects fzr in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. Fzr, a member of the 7WD domain family, plays a crucial role in cell cycle regulation, particularly in B-cell tumorigenesis. Fzr (AR38.2) antibody helps study how fzr negatively regulates levels of key mitotic cyclins, including cyclins A, B, and B3, thereby influencing cell cycle progression. Loss of fzr leads to an additional division cycle in the epidermis and disrupts endoreduplication in the salivary gland, which can significantly impact tissue development and cancer progression. Fzr overexpression enhances the susceptibility of B-lymphoma cells to natural killer cell cytotoxicity, indicating potential as a therapeutic target in cancer treatment. Anti-fzr antibody (AR38.2) serves as an essential tool for researchers investigating cell cycle regulation and tumor suppression mechanisms.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
fzr Antibody (AR38.2) References:
- Overexpression of murine fizzy-related (fzr) increases natural killer cell-mediated cell death and suppresses tumor growth. | Wang, CX., et al. 2000. Blood. 96: 259-63. PMID: 10891459
- The APC/C activator FZR1 coordinates the timing of meiotic resumption during prophase I arrest in mammalian oocytes. | Holt, JE., et al. 2011. Development. 138: 905-13. PMID: 21270054
- Targeting of Fzr/Cdh1 for timely activation of the APC/C at the centrosome during mitotic exit. | Meghini, F., et al. 2016. Nat Commun. 7: 12607. PMID: 27558644
- Identification of the APC/C co-factor FZR1 as a novel therapeutic target for multiple myeloma. | Crawford, LJ., et al. 2016. Oncotarget. 7: 70481-70493. PMID: 27655696
- FZR1 loss increases sensitivity to DNA damage and consequently promotes murine and human B-cell acute leukemia. | Ishizawa, J., et al. 2017. Blood. 129: 1958-1968. PMID: 28143883
- The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function. | Wan, L., et al. 2017. Cancer Discov. 7: 424-441. PMID: 28174173
- Insufficiency of FZR1 disturbs HSC quiescence by inhibiting ubiquitin-dependent degradation of RUNX1 in aplastic anemia. | Zhou, C., et al. 2022. Leukemia. 36: 834-846. PMID: 34635784
- De novo FZR1 loss-of-function variants cause developmental and epileptic encephalopathies. | Manivannan, SN., et al. 2022. Brain. 145: 1684-1697. PMID: 34788397
- Association of Hsp90 with p53 and Fizzy related homolog (Fzr) synchronizing Anaphase Promoting Complex (APC/C): An unexplored ally towards oncogenic pathway. | Chowdhury, SR., et al. 2023. Biochim Biophys Acta Rev Cancer. 1878: 188883. PMID: 36972769
- N 6-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer. | Su, J., et al. 2023. Cancer Res. 83: 3059-3076. PMID: 37326469
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
fzr Antibody (AR38.2) | sc-53291 | 200 µg/ml | $322.00 | |||
fzr Antibody (AR38.2): m-IgGκ BP-HRP Bundle | sc-520967 | 200 µg Ab, 40 µg BP | $361.00 |